Tykerb (Head and Neck Cancer) - Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Tykerb (Head and Neck Cancer) - Analysis and Forecasts to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Tykerb(Head and Neck Cancer )-Analysis and Forecasts to 2020' provides Zelapar sales
forecast the forecast period (2014-2020). The report also includes information on Head and Neck Cancer market. This report is built
using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's
corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third
party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Tykerb including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Tykerb including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2014-2020 forTykerb in the US & UK

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3
2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4

Tykerb (Head and Neck Cancer) - Analysis and Forecasts to 2020 (From Slideshare) Page 1/6


2.3 Etiology 9
2.4 GlobalData Analysis and Forecasts Report Guidance 10
3 Head and Neck Cancer Disease: Market Characterization 11
3.1 Head and Neck Cancer Disease Market 11
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 11
3.3 Drivers for the Head and Neck Cancer Disease Market 12
3.3.1 High Incidence 12
3.3.2 Low Initial Diagnosis Rate 13
3.3.3 Emergence of Targeted Therapies and Vaccines 13
4 Tumor'Node'Metastases (TNM) Classification of Head and Neck Cancer 14
5 Tykerb 22
5.1 Introduction 22
5.2 Mechanism of Action 22
5.3 Clinical Studies 22
5.4 Approval History of Tykerb 23
5.5 Factors Affecting Sales of Tykerb 23
5.5.1 Head and Neck Cancer Market 23
5.5.2 High Efficacy 23
5.5.3 Oral Dosing 23
5.5.4 Superiority of Targeted Therapy 24
5.6 Drug Risk Benefit Score 24
5.6.1 Efficacy 24
5.6.2 Safety 24
5.6.3 Compliance 24
5.6.4 Dosing Convenience 25
5.7 Intensity of Competition 25
5.8 Sales forecast 25
5.8.1 Target patient Pool of Tykerb 25
5.8.2 Dosing 26
5.8.3 Market Penetration 26
5.8.4 Annual Cost of Therapy 26
5.8.5 Sales Projections of Tykerb 27
6 Head and Neck Cancer Market: Appendix 36
6.1 Market Definitions 36
6.2 List of Abberiviations 36
6.3 Research Methodology 36
6.3.1 Coverage 37
6.3.2 Secondary Research 37
6.3.3 Forecasting 37
6.3.4 Number of Patients Approved to take the Drug 38
6.3.5 Net Penetration of Drug 38
6.3.6 Net Annual Dosing 39
6.3.7 Annual Cost of Therapy 39
6.3.8 Primary Research 39
6.3.9 Expert Panels 40
6.4 Contact Us 40
6.5 Disclaimer 40
6.6 Sources 40



1.1 List of Tables

Table 1: Head and Neck Cancer Incidences and Mortality, 2008-2030 4
Table 2: Head and Neck Cancer, Market Forecasts ($bn), Global, 2009'2020 11
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 14
Table 4: TNM Classification of the Nasopharyngeal Cancer 19
Table 5: Patent Approval and Expiry 23
Table 6: Drug Risk Benefit Score 24
Table 7: Head and Neck Cancer, The US, EU-5 and Japan, Sales Forecast for Tykerb ($m), 2014'2020 27
Table 8: Head and Neck Cancer, The US, Sales Forecast for Tykerb ($m), 2014'2020 28
Table 9: Head and Neck Cancer, The UK, Sales Forecast for Tykerb ($m), 2014'2020 29
Table 10: Head and Neck Cancer, France, Sales Forecast for Tykerb ($m), 2014'2020 30
Table 11: Head and Neck Cancer, Germany, Sales Forecast for Tykerb ($m), 2014'2020 31
Table 12: Head and Neck Cancer, Italy, Sales Forecast for Tykerb ($m), 2014'2020 32
Table 13: Head and Neck Cancer, Spain, Sales Forecast for Tykerb ($m), 2014'2020 33
Table 14: Head and Neck Cancer, Japan, Sales Forecast for Tykerb ($m), 2014'2020 34

1.2 List of Figures

Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence ' Global, 2008 5
Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality ' Global, 2008 6
Figure 3: Difference between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 7
Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 8
Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 8
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 9
Figure 7: Head and Neck Cancer, Market Forecasts ($bn), Global, 2009'2020 11
Figure 8: Oncology Incidence (in billion), Global, 2008-2030 12
Figure 9: Head and Neck Cancer Incidence (in billion), Global, 2008-2030 12
Figure 10: Broad Classification of Head and Neck Cancer 14
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 15
Figure 12: Detailed TNM Classification of Laryngeal Cancer 16
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 17
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 18
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 20
Figure 16: Classification of Head and Neck Cancer 21
Figure 17: Drug Model Diagram of Tykerb 25
Figure 18: Drug Dosage Diagram of Tykerb 26
Figure 19: Head and Neck Cancer , The US, EU-5 and Japan, Sales Forecast for Tykerb ($m), 2014'2020 27
Figure 20: Head and Neck Cancer , The US, Sales Forecast for Tykerb ($m), 2014'2020 28
Figure 21: Head and Neck Cancer , The UK, Sales Forecast for Tykerb ($m), 2014'2020 29
Figure 22: Head and Neck Cancer , France, Sales Forecast for Tykerb ($m), 2014'2020 30
Figure 23: Head and Neck Cancer , Germany, Sales Forecast for Tykerb ($m), 2014'2020 31
Figure 24: Head and Neck Cancer , Italy, Sales Forecast for Tykerb ($m), 2014'2020 32
Figure 25: Head and Neck Cancer , Spain, Sales Forecast for Tykerb ($m), 2014'2020 33
Figure 26: Head and Neck Cancer , Japan, Sales Forecast for Tykerb ($m), 2014'2020 34
Figure 27: Tykerb, Head and Neck Cancer, Sales Forecast by Country ($m), 2020 35
Figure 28: GlobalData Methodology 36
Figure 29: Drug Model Diagram 38



Figure 30: Patients Approved for the Drug 39


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Tykerb (Head and Neck Cancer) - Analysis and Forecasts to 2020

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (18)

More from ReportLinker.com

More from ReportLinker.com (20)

Tykerb (Head and Neck Cancer) - Analysis and Forecasts to 2020